.jpg "Rexahn Pharma (NYSE MKT: RNN)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rexahn Pharma (NYSE MKT: RNN), SCYNEXIS (NASDAQ: SCYX) and Aratana (NASDAQ: PETX) with bullish sentiments.
Rexahn Pharma (NYSE MKT: RNN)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rexahn Pharma (NYSE MKT: RNN), with a price target of $19.50. The company’s shares closed on Friday at $2.21.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -13.3% and a 34.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Rexahn Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.
See today’s analyst top recommended stocks >>
SCYNEXIS (NASDAQ: SCYX)
SCYNEXIS (NASDAQ: SCYX) received a Buy rating and a $5 price target from H.C. Wainwright analyst Oren Livnat today. The company’s shares closed on Friday at $1.17, close to its 52-week low of $1.05.
According to TipRanks.com, Livnat is ranked 0 out of 5 stars with an average return of -11.3% and a 26.5% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
SCYNEXIS has an analyst consensus of Moderate Buy, with a price target consensus of $5.
Aratana (NASDAQ: PETX)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Aratana (NASDAQ: PETX), with a price target of $10. The company’s shares closed on Friday at $5.07.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 4.4% and a 35.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
Aratana has an analyst consensus of Strong Buy, with a price target consensus of $8.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
